Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Silo Pharma Inc (NQ: SILO ) 1.200 +0.070 (+6.19%) Streaming Delayed Price Updated: 3:59 PM EDT, Sep 5, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Silo Pharma Inc < Previous 1 2 3 4 5 Next > Silo Pharma Inc. (NASDAQ: SILO) Set to Benefit as Study Supports the Efficacy of Psychedelics in Treating ‘Drug-Resistant’ Depression March 13, 2023 Via Investor Brand Network Exposures COVID-19 PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Expands Intellectual Property, Technology Rights for Treating Rare Stress-Related Medical Conditions March 03, 2023 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Silo Pharma Inc. (NASDAQ: SILO) Granted US Patent For SPC-15 to Prevent and Treat Stress-Induced Disorders February 22, 2023 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Patent for Treatment of Alzheimer’s February 13, 2023 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Silo Pharma Announces Filing of Patent for Treatment of Alzheimer’s February 13, 2023 From Silo Pharma, Inc. Via GlobeNewswire BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Partnering to Transform Health Care, Improve Patient Outcomes February 07, 2023 Via Investor Brand Network PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Expands IP Portfolio with New USPTO Patent February 02, 2023 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Silo Pharma Announces Expansion of Intellectual Property Portfolio February 02, 2023 Silo Receives Issuance of U.S. Patent Covering SPC-15 Method for Treatment and Prevention of Stress-Induced Affective Disorders From Silo Pharma, Inc. Via GlobeNewswire PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Board Authorizes Stock Repurchase Program January 31, 2023 Via Investor Brand Network Silo Pharma Announces Stock Repurchase Program January 31, 2023 From Silo Pharma, Inc. Via GlobeNewswire Silo Pharma Inc. (NASDAQ: SILO) Provides Update on UCSF Psylocibin Clinical Trial January 26, 2023 Via Investor Brand Network PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Eying Broad Market Opportunities for Its Liposomal Joint Homing Peptide January 20, 2023 Via Investor Brand Network Silo Pharma Inc. (NASDAQ: SILO) Provides Positive Update on Ongoing Study into the Use of Joint Homing Peptides as an Alternative Treatment for Rheumatoid Arthritis January 12, 2023 Via Investor Brand Network InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances Clinical Study Examining Psilocybin’s Effect on Inflammation January 10, 2023 Via Investor Brand Network Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation January 10, 2023 From Silo Pharma, Inc. Via GlobeNewswire InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Reports Positive Results from SPU- 21 Arthritis Study January 03, 2023 Via Investor Brand Network Silo Pharma (NASDAQ: SILO) Reports Positive Results from Dose Optimization Study for SPU-21 and Treatment of Arthritis December 30, 2022 Silo Pharma, Inc. (NASDAQ: SILO) operates as a development-stage biopharmaceutical company, which is focused on combining traditional therapies with psychedelics Via Spotlight Growth Global Rheumatoid Arthritis Drugs Market Expected To Hit US$ 70 Billion By 2030 December 30, 2022 EQNX::TICKER_START (NASDAQ:SILO),(NASDAQ:BXRX),(NASDAQ:HOTH),(NASDAQ:KALA),(NASDAQ:NUWE) EQNX::TICKER_END Via FinancialNewsMedia Silo Pharma Announces Positive Study Results of SPU December 30, 2022 21 for Arthritis – SPU-21 effective in controlling arthritis progression SPU-21 Demonstrates Positive Data in Arthritis Suppression using Silo’s Novel Joint Homing Peptide Englewood Cliffs, – December... Via FinancialNewsMedia Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis December 30, 2022 From Silo Pharma, Inc. Via GlobeNewswire InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) CEO Discusses Advancement of Pipeline, Positioning in Shareholder Letter December 01, 2022 Via Investor Brand Network Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine December 01, 2022 From Silo Pharma, Inc. Via GlobeNewswire PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advancing Research of SPU-21 in Human Synovial Tissue November 21, 2022 Via Investor Brand Network Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue November 21, 2022 From Silo Pharma, Inc. Via GlobeNewswire PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Milestone in IND-Enabling Study of Time-Released Ketamine Formulation November 11, 2022 Via Investor Brand Network Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation November 11, 2022 From Silo Pharma, Inc. Via GlobeNewswire New Psychedelic Journal to Focus on Publishing Psychedelic Research November 07, 2022 Via Investor Brand Network Silo Pharma Inc. (NASDAQ: SILO) Extends Columbia University Agreement to Continue Research for Therapeutics to Treat Alzheimer’s Disease November 04, 2022 Via Investor Brand Network PsychedelicNewsBreaks – Silo Pharma Inc. (SILO) Confident in Preclinical Work on Its Novel Ketamine Formulation November 03, 2022 Via Investor Brand Network Microscopy Provides Insights on Psychedelics Action Inside Neuropathways October 28, 2022 Via Investor Brand Network < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.